These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 24884318)
1. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318 [TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia. Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017 [TBL] [Abstract][Full Text] [Related]
3. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
4. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995 [TBL] [Abstract][Full Text] [Related]
5. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation. Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095 [TBL] [Abstract][Full Text] [Related]
8. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene. Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177 [TBL] [Abstract][Full Text] [Related]
10. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
11. [Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells]. Ge YQ; Cheng RB; Yang B; Huang Z; Chen Z Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2389-95. PubMed ID: 26591531 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
13. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515 [TBL] [Abstract][Full Text] [Related]
14. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells. Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167 [TBL] [Abstract][Full Text] [Related]
15. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells. Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662 [TBL] [Abstract][Full Text] [Related]
17. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884 [TBL] [Abstract][Full Text] [Related]
18. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Rahmani M; Nguyen TK; Dent P; Grant S Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
20. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]